E-MTAB-6432 - Progression of KRas^G12D;Rosa26-MYC tumours to invasive disease

Status
Submitted on 19 February 2014, released on 1 June 2018, last updated on 13 March 2020
Organism
Mus musculus
Samples (8)
Protocols (8)
Description
The aim of the study was to investigate gene expression tumour progression of KRas*/MYC driven lung tumours from adenocarcinoma in situ to invasive disease.
Experiment types
RNA-seq of coding RNA, disease state design
Contact
Citations
The ERBB network facilitates KRAS-driven lung tumorigenesis. Kruspig B, Monteverde T, Neidler S, Hock A, Kerr E, Nixon C, Clark W, Hedley A, Laing S, Coffelt SB, Le Quesne J, Dick C, Vousden KH, Martins CP, Murphy DJ. 10(446) (2018), PMID:29925636
Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma. Neidler S, Kruspig B, Hewit K, Monteverde T, Gyuraszova K, Braun A, Clark W, James D, Hedley A, Nieswandt B, Shanks E, Dick C, Murphy DJ. 11(5) (2019), PMID:31032816
MINSEQE
Exp. designProtocolsVariablesProcessedSeq. reads
Files
Investigation descriptionE-MTAB-6432.idf.txt
Sample and data relationshipE-MTAB-6432.sdrf.txt
Links